AxoGen, Inc. (currently NASDAQ: AXGN, formerly OTCQB: AXGN), a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, today announced the pricing of the underwritten offering of 6,000,000 shares of its common stock at a price to the public of $3.00 per share generating gross proceeds of approximately $18 million, excluding the underwriters’ over-allotment option and deductions for underwriting discounts and commissions and estimated expenses.
AxoGen will use the net proceeds from the offering to expand product commercialization and marketing efforts for its portfolio of peripheral nerve repair products (Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector); to further develop its product pipeline; and for general working capital purposes. This offering is expected to close on Aug. 14, subject to customary closing conditions.
A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. The registration statement may be accessed through the SEC’s website at www.sec.gov. JMP Securities LLC is acting as the sole book-running manager in the offering and Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., is acting as co-manager.
All of the shares of common stock in this offering are to be sold by AxoGen. AxoGen has granted the underwriters a 30-day option to purchase up to an aggregate of 900,000 additional shares of common stock at the public offering price, less the underwriting discount, to cover over-allotments, if any.